ALN-4324 for Type 2 Diabetes
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
Who Is on the Research Team?
Medical Director
Principal Investigator
Alnylam Pharmaceuticals
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single dose of ALN-4324 or placebo
Follow-up
Participants are monitored for changes in insulin sensitivity and other measures
What Are the Treatments Tested in This Trial?
Interventions
- ALN-4324
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Participants will be administered a single dose of ALN-4324.
Participants will be administered a single dose of placebo.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Alnylam Pharmaceuticals
Lead Sponsor
Dr. Yvonne Greenstreet
Alnylam Pharmaceuticals
Chief Executive Officer since 2021
MD from the University of Leeds, MBA from INSEAD
Dr. Pushkal Garg
Alnylam Pharmaceuticals
Chief Medical Officer since 2016
MD from Columbia University
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.